Compare Quest Diagnostics Inc (DGX) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Gitlab Inc — how do they compare? Quest Diagnostics Inc trades at $205.48 (market cap $22.80B), while Gitlab Inc trades at $33.57 (market cap $5.57B). The key difference: Quest Diagnostics Inc is far larger — about 4.1× Gitlab Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| DGX | GTLB | |
|---|---|---|
Market Cap | $22.80B | $5.57B |
Sector | Health | Technology |
52-Week High | $216.02 | $51.04 |
52-Week Low | $166.42 | $19.42 |
Enterprise Value | $28.82B | $4.31B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
GitLab (GTLB) trades at $33.47, up 3.24% today, with a bullish technical signal from moving averages and a consensus analyst price target of $31.93. The company reported strong revenue growth to $759.25 million in 2025, though it remains unprofitable with a net margin of -2.49%. Recent news highlights its leadership in DevSecOps and AI-driven platform expansions, including a collaboration with Google Cloud.
The outlook is mixed; robust revenue growth and strategic positioning in AI and DevSecOps offer upside, but profitability challenges and high valuation multiples pose risks. Analyst sentiment is cautious with a majority hold rating, reflecting concerns over near-term execution versus long-term potential in the enterprise software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
